Novartis, Genentech Lose Asthma Drug Patent In Netherlands
Celltrion Inc. has persuaded a Dutch court to revoke Novartis and Genentech's patent in the Netherlands for asthma drug omalizumab, straying from a London judge's recent decision to uphold the U.K....To view the full article, register now.
Already a subscriber? Click here to view full article